{"nctId":"NCT00988156","briefTitle":"Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children","startDateStruct":{"date":"2007-12-07","type":"ACTUAL"},"conditions":["Partial Epilepsy in Children and Adolescents"],"count":304,"armGroups":[{"label":"Eslicarbazepine acetate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Eslicarbazepine acetate (BIA 2-093)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Eslicarbazepine acetate"]}],"interventions":[{"name":"Eslicarbazepine acetate (BIA 2-093)","otherNames":["BIA 2093"]},{"name":"Eslicarbazepine acetate","otherNames":["BIA 2093"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* girls of child-bearing potential have to follow reliable and medically acceptable contraceptive method throughout the study\n* diagnosis of epilepsy for at least 6 months prior to enrolment\n* at least 4 partial-onset seizures in the last month prior to enrolment despite stable therapy with adequate dosage of 1 or 2 AEDs\n* at least 4 partial-onset seizures during each 4-week interval of the 8-week baseline period\n* previous treatment with three or more AEDs, in their maximum tolerated doses, for at least one month, without seizure control\n* current treatment with 1 or 2 AEDs (any except oxcarbazepine); if present, vagus nerve stimulation is considered an AED\n* stable dose regimen of AEDs during the 8-week baseline period\n* cooperation and willingness to complete all aspects of the study, including hospitalisation if required\n* written informed consent to participate in the study in accordance with local legislation\n\nExclusion Criteria:\n\n* primarily generalised seizures\n* baseline seizure frequency substantially different from usual seizure frequency\n* known progressive neurological disorders\n* history of status epilepticus within the 3 months prior to enrolment\n* seizures of non-epileptic origin\n* Lennon-Gastaut\n* West syndrome\n* Major psychiatric disorders\n* Previous treatment any study with Eslicarbazepine acetate","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Seizure Frequency","description":"Relative reduction in the standardised 4-week seizure frequency from the baseline period to the 12-week maintenance period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":"186.19"},{"groupId":"OG001","value":"36.6","spread":"72.47"}]}]}]},{"type":"PRIMARY","title":"Responder Rate","description":"Responder rate defined as the number of patients with at least a 50% decrease in the standardised 4-week seizure frequency from the baseline period to the 12-week maintenance period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":129},"commonTop":["Nasopharyngitis","Convulsion","Headache","Somnolence","Pharyngitis"]}}}